Posts tagged commercial opportunity
Leerink starts Aclaris at OP

Leerink initiated coverage of Aclaris Therapeutics (NASDAQ:ACRS) with an “outperform” rating and $54 price target. The stock closed at $28.04 on Monday.

Read More
HCW starts Aviragen Therapeutics at buy

H.C. Wainwright launched coverage of Aviragen Therapeutics (NASDAQ:AVIR) with a “buy” rating and price target of $5. The stock closed at $1.43 on Tuesday.

Aviragen is a developing three direct-acting antiviral (DAA) compounds, each in Phase 2 development, including oral vapendavir, which targets human rhinovirus (HRV), causing the common cold; oral BTA585, which targets respiratory syncytial virus; and BTA074, which is a topical targeting human papillomavirus for condyloma.

Read More